---
schema_version: "secwatch.filing_event.v1"
accession: "0001645113-23-000036"
form_type: "8-K"
ticker: "NVCR"
cik: "0001645113"
company_name: "NovoCure Ltd"
filed_at: "2023-04-26T23:59:59+00:00"
generated_at: "2026-06-16T13:02:01.156978+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Novocure LUNAR phase 3 NSCLC trial met primary endpoint; results at ASCO 2023

## Summary
- LUNAR trial showed statistically significant improvement in overall survival with TTFields plus standard therapies in metastatic NSCLC.
- Full results to be presented as a late-breaking abstract at ASCO 2023 on June 6, 2023, at 11:09 a.m. CDT.
- Novocure will host an investor event on June 6 at 2 p.m. CDT to discuss the data.
- First phase 3 trial evaluating TTFields outside the brain and with immunotherapy.
- Ten abstracts on TTFields therapy, including LUNAR, will be presented at ASCO 2023.

## SEC filing metadata
- accession: 0001645113-23-000036
- form_type: 8-K
- ticker: NVCR
- cik: 0001645113
- company_name: NovoCure Ltd
- filed_at: 2023-04-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645113/000164511323000036/0001645113-23-000036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645113/000164511323000036/nvcr-20230426.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001645113-23-000036
- JSON: https://secwatch.observer/filing/0001645113-23-000036.json
- Plain text: https://secwatch.observer/filing/0001645113-23-000036.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.